Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Hikma Pharmaceuticals PLC - London-based generic drugmaker - Completes acquisition of Custopharm Inc from Water Street Healthcare Partners, following approval from the US Federal Trade Commission. Back in September, Hikma agreed to buy the California-based generic injectable products company for a total of up to $425 million. Deal will add up to 13 approved products and additional pipeline products.
Current stock price: 2,046.00 pence
12-month change: down 16%
Copyright 2022 Alliance News Limited. All Rights Reserved.